GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CalciMedica Inc (NAS:CALC) » Definitions » 1-Year ROIIC %

CalciMedica (CalciMedica) 1-Year ROIIC % : 4,037.31% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is CalciMedica 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. CalciMedica's 1-Year ROIIC % for the quarter that ended in Mar. 2024 was 4,037.31%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for CalciMedica's 1-Year ROIIC % or its related term are showing as below:

CALC's 1-Year ROIIC % is ranked better than
97.8% of 1453 companies
in the Biotechnology industry
Industry Median: -4.79 vs CALC: 4037.31

CalciMedica 1-Year ROIIC % Historical Data

The historical data trend for CalciMedica's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CalciMedica 1-Year ROIIC % Chart

CalciMedica Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial -306.73 210.48 1,128.67 -1,789.65 2,078.50

CalciMedica Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.69 284.98 975.54 2,078.50 4,037.31

Competitive Comparison of CalciMedica's 1-Year ROIIC %

For the Biotechnology subindustry, CalciMedica's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CalciMedica's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CalciMedica's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where CalciMedica's 1-Year ROIIC % falls into.



CalciMedica 1-Year ROIIC % Calculation

CalciMedica's 1-Year ROIIC % for the quarter that ended in Mar. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -21.502 (Mar. 2024) - -32.322 (Mar. 2023) )/( 0.552 (Mar. 2024) - 0.284 (Mar. 2023) )
=10.82/0.268
=4,037.31%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


CalciMedica  (NAS:CALC) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


CalciMedica 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of CalciMedica's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


CalciMedica (CalciMedica) Business Description

Traded in Other Exchanges
N/A
Address
274 Redwood Shores Parkway, P.O. Box 144, Redwood City, CA, USA, 94065
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.
Executives
Robert N Wilson director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
A. Rachel Leheny director, 10 percent owner, officer: Chief Executive Officer C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Eric W Roberts director, 10 percent owner, officer: Chief Business Officer VALENCE LIFE SCIENCES LLC, 500 PARK AVENUE 9TH FLOOR, NEW YORK NY 10022
Sudarshan Hebbar officer: Chief Medical Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Fred A Middleton director, 10 percent owner 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Sanderling Ventures Vii (canada), L.p. 10 percent owner 1300 S. EL CAMINO REAL, SUITE 203, SAN MATEO CA 94402
Sanderling Ventures Management Vi 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Beteiligungs Gmbh & Co Kg 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Vi Limited Partnership 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Co Investment Fund Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Sanderling Venture Partners Vi Lp 10 percent owner 1300 S EL CAMINO REAL SUITE 203, SAN MATEO CA 94402
Allan Shaw director C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Michael J. Dunn officer: President and COO C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037
Kenneth A. Stauderman officer: Chief Scientific Officer C/O CALCIMEDICA, INC., 505 COAST BOULEVARD SOUTH, LA JOLLA CA 92037